160 related articles for article (PubMed ID: 38026602)
1. Switching to Conbercept in Diabetic Macular Edema After Unsatisfactory Response to Previous Intravitreal Injection of Ranibizumab.
Xing P; Meng B; Hu X; Qu W; Wang S
Clin Ophthalmol; 2023; 17():3491-3497. PubMed ID: 38026602
[TBL] [Abstract][Full Text] [Related]
2. One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema.
Zhou Q; Guo C; You A; Wang D; Wang W; Zhang X
Mol Vis; 2019; 25():636-644. PubMed ID: 31700228
[TBL] [Abstract][Full Text] [Related]
3. Comparison of conbercept and ranibizumab for the treatment efficacy of diabetic macular edema: a Meta-analysis and systematic review.
Liu WS; Li YJ
Int J Ophthalmol; 2019; 12(9):1479-1486. PubMed ID: 31544046
[TBL] [Abstract][Full Text] [Related]
4. Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection.
Nawar AE; Wasfy T; Shafik HM
BMC Ophthalmol; 2022 Jun; 22(1):287. PubMed ID: 35768859
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.
Xu Y; Rong A; Xu W; Niu Y; Wang Z
BMC Ophthalmol; 2017 Aug; 17(1):158. PubMed ID: 28841827
[TBL] [Abstract][Full Text] [Related]
6. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
[No Abstract] [Full Text] [Related]
7. Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis.
Wang X; He X; Qi F; Liu J; Wu J
Front Pharmacol; 2022; 13():876386. PubMed ID: 35814207
[No Abstract] [Full Text] [Related]
8. [Treatment response to Conbercept of different types of diabetic macular edema classified based on optical coherence tomography].
Zhang Y; Yao J; Quan Y; Wang J; Xing Y; Zhou A
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1501-1508. PubMed ID: 34755665
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
[TBL] [Abstract][Full Text] [Related]
10. Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema.
Wei Q; Wan Z; Hu Y; Peng Q
Drug Des Devel Ther; 2019; 13():4367-4374. PubMed ID: 31920286
[TBL] [Abstract][Full Text] [Related]
11. Hyperreflective foci in OCT image as a biomarker of poor prognosis in diabetic macular edema patients treating with Conbercept in China.
Liu S; Wang D; Chen F; Zhang X
BMC Ophthalmol; 2019 Jul; 19(1):157. PubMed ID: 31337360
[TBL] [Abstract][Full Text] [Related]
12. Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis.
Zhou P; Zheng S; Wang E; Men P; Zhai S
Front Pharmacol; 2021; 12():696201. PubMed ID: 34712132
[No Abstract] [Full Text] [Related]
13. Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration.
Wang Z; Li M; Yao Y; Hu J; Tang J; Tang R; Piao Z; Qu J
J Ophthalmol; 2020; 2020():9340356. PubMed ID: 33005448
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Efficacy of Intravitreal Conbercept Injections with or without Focal Macular Photocoagulation for Diabetic Macular Edema.
Mao Y; Wang S; Ji X; Cao K; Hou S; Xiao Y
Altern Ther Health Med; 2023 Jul; 29(5):308-313. PubMed ID: 37171942
[TBL] [Abstract][Full Text] [Related]
15. Response to Initial Anti-Vascular Endothelial Growth Factor for Diabetic Macular Edema Is Significantly Correlated with Response to Third Consecutive Monthly Injection.
Maeda S; Sugimoto M; Tenma Y; Tsukitome H; Kato K; Chujo S; Matsui Y; Matsubara H; Kondo M
J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362644
[TBL] [Abstract][Full Text] [Related]
16. Panretinal photocoagulation after or prior to intravitreal conbercept injection for diabetic macular edema: a retrospective study.
Zhang W; Zhao G; Fan W; Zhao T
BMC Ophthalmol; 2021 Apr; 21(1):160. PubMed ID: 33789617
[TBL] [Abstract][Full Text] [Related]
17. Three year outcomes of intravitreal ranibizumab and aflibercept treatment of patients with diabetic macular edema: A comparative study.
Akbas YB; Alagoz C; Cakmak S; Demir G; Alagoz N; Artunay HO
Ther Adv Ophthalmol; 2023; 15():25158414231195174. PubMed ID: 37649968
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis.
Liu Y; Cheng J; Gao Y; Qin L; Min X; Zhang M
Ann Transl Med; 2020 Mar; 8(6):382. PubMed ID: 32355826
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal Dexamethasone in Diabetic Macular Oedema: A Way of Enhancing the Response to Anti-VEGF in Non- or Poor Responders?
Touhami S; Dupas B; Bertaud S; Tadayoni R; Couturier A
Ophthalmologica; 2022; 245(4):350-357. PubMed ID: 34587614
[TBL] [Abstract][Full Text] [Related]
20. Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review.
Yuen YS; Tan GSW; Gan NY; Too IHK; Mothe RK; Basa P; Shaikh J
Clin Ophthalmol; 2022; 16():3503-3526. PubMed ID: 36274678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
